News for Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Corp. (AVXL) has bolstered its Scientific Advisory Board by welcoming Professor Dr. Audrey Gabelle, MD, PhD. Dr. Gabelle is renowned for he

**media[602841]**

Anavex Life Sciences (AVXL) presented significant findings at the 9th International Conference on Alzheimer's Disease in Abu Dhabi. The presentation foc

**media[600326]**

Anavex Life Sciences Corp. (AVXL) showcases promising long-term results for its Alzheimer's drug in the ATTENTION-AD trial. Analysts predict a significa

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œCompany”) ( AVXL), a clinical-stage biopharmaceutical company

**media[548363]**

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAVXL.OQ - Anavex Life Sciences CorpQ1 2025 Anavex Life Sciences Corp Earnings CallFeb 12, 2025

Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this year. Click for my AVXL stockupdate.

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsClint Tomlinson - IRChristopher...

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œComp

Anavex (AVXL) reports Q1 GAAP EPS of -$0.14, beating estimates by $0.03, with $120.8M cash on hand ensuring a 4-year runway.

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (”œAnavex” or the ”œCompany”) ( AVXL), a clinical-stage biopharmaceutical company

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Blarcamesine potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement Impairment of autophagy precedes bot

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease